Qudexy® XR (topiramate) Extended-Release Capsules are indicated for:
- Migraine: Preventive treatment of migraine in patients 12 years and older.
- Epilepsy: Initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years and older. Adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut Syndrome in patients 2 years and older.
Redefining patient-centric treatment
Qudexy® XR demonstrates our commitment to provide affordable options to patients and health care professionals, and we’ll continue to develop innovative treatments.